Medpace Holdings, Inc. (MEDP) Average Return on Equity (ROE)
The current return on equity (roe) for Medpace Holdings, Inc. (MEDP) is N/A as of Thursday, June 18, 2026, shown against its trailing averages.
Average Return on Equity (ROE) Chart
MEDP Return on Equity (ROE) Averages
RETURN ON EQUITY (ROE) CURRENT
N/A
RETURN ON EQUITY (ROE) TTM
73.63%
RETURN ON EQUITY (ROE) 3Y
65.34%
RETURN ON EQUITY (ROE) 5Y
49.74%
RETURN ON EQUITY (ROE) 10Y
30.23%
RETURN ON EQUITY (ROE) 15Y
25.29%
RETURN ON EQUITY (ROE) 20Y
25.29%
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle